Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $90,000.

  • Day One Biopharmaceuticals' Depreciation & Amortization (CF) rose 462.50% to $90,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $313,000, marking a year-over-year increase of 367.16%. This contributed to the annual value of $92,000 for FY2024, which is 155.56% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Depreciation & Amortization (CF) stood at $90,000, which was down 1.10% from $91,000 recorded in Q2 2025.
  • Day One Biopharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $94,000 during Q1 2025, with a 5-year trough of $6,000 in Q1 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $16,000 (2024), whereas its average is $36,636.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Depreciation & Amortization (CF) plummeted by 69.44% in 2023, and later soared by 506.67% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $15,000 in 2022, then fell by 13.33% to $13,000 in 2023, then skyrocketed by 192.31% to $38,000 in 2024, then soared by 462.50% to $90,000 in 2025.
  • Its last three reported values are $90,000 in Q3 2025, $91,000 for Q2 2025, and $94,000 during Q1 2025.